Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

BEDMINSTER, N.J., Nov. 1 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today reported its financial results for the quarter ended September 30, 2007 and provided an update on its 2007 milestones and financial guidance.

Update on 2007 Milestones

With the confirmation of its partnership with Nycomed to develop GATTEX(TM) (teduglutide) outside North America, NPS has now met or exceeded all of its key corporate milestones for 2007. The company announced that it has:

-- Completed the Phase 3 study of GATTEX in short bowel syndrome and

announced top-line results in October;

-- Secured a development and commercialization partner for one of its

late-stage programs;

-- Monetized non-core assets to raise cash;

-- Retired substantially all of its 2008 convertible debt;

-- Reduced cash burn guidance to $70 to $80 million from previous guidance

of $80 to $90 million;

-- Positioned the company to burn between $35 and $45 million in 2008;

-- Explored the development of PREOS and GATTEX in at least one new

indication for each program.

Dr. Tony Coles, president and CEO of NPS, stated: "Our team's diligent efforts this year have strengthened our balance sheet and increased our operating flexibility to drive our late-stage products forward. By monetizing our non-core assets and addressing our debt, we are in a much stronger position to maximize the value of GATTEX and PREOS for patients and shareholders. As a result of the improvements in our financial profile, we are revising our 2007 guidance to reflect the transformation our business has undergone this year."

Business Highlights and Revised 2007 Financial Guidanc
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... March 18 InterMune, Inc.,(Nasdaq: ITMN ) ... former employee in connection with the promotional activities ... in June of,2003., "Today,s indictment concerns conduct ... than four years ago., "In 2006, InterMune ...
... HOPKINTON, Mass., March 18 Caliper Life,Sciences, Inc. ... presentation at the,Lehman Brothers Global Healthcare Conference in ... 5:15 p.m. EDT. Kevin Hrusovsky, President and CEO ... company,s business. The live,webcast can be accessed at, ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... it will,report results for its fourth quarter and year-end ... A conference call to review the results will ... 26, 2008 and will be hosted by Anthony DiTonno,President ...
Cached Biology Technology:Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct 2Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct 3NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 2NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 3
(Date:7/11/2014)... new professorship in tissue engineering to promote innovative ... and the Marine Biological Laboratory, supported by a ... Bell Foundation., The Eugene Bell Professorship in Tissue ... Engineering. That endowed chair holder also will direct ... Center for Regenerative Biology and Tissue Engineering, and ...
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2Molecular snapshots of oxygen formation in photosynthesis 2
... caused by bisphenol A (BPA) presence in reusable plastic ... made with supposed BPA-free materials. Prompted by requests ... wanted to see if these alternativesincluding products made with ... an option free of BPA. In a study ...
... Fla. (July. 11, 2011) A study published ... (20:5) investigating optimal routes for transplanting neural stem/progenitor cells ... has demonstrated that intralesional (IL) injection conferred benefits over ... study, by a team of Keio University (Japan) researchers, ...
... contribution to marine science and a superb way of ... into a format and language that can only enhance ... senior vice president for marine conservation and chief scientist ... climate, nurture marine ecosystems full of aquatic life, and ...
Cached Biology News:Research shows 'BPA-free' bottles live up to manufacturers' claims 2Research shows 'BPA-free' bottles live up to manufacturers' claims 3Neural stem progenitor cell transplantation’s potential to aid spinal cord injury tested 2
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 5,000 units polymerase, ...
... the formation of a phosphodiester bonds between ... duplex DNA molecules or between oligonucleotides which ... at 45 - 65?. Tfi DNA Ligase ... temperatures than conventional DNA ligases, Thus, Tfi ...
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and ... royalties for your hard work and endeavour! ... build it up,and market it internationally. We ...
Biology Products: